Sera Prognostics
Diagnostic company developing blood tests to predict risk of premature delivery.
What they do
The company develops and markets clinical blood tests that assess the biological risk of premature birth. Its main diagnostic test measures proteins in blood during pregnancy to identify asymptomatic women at high risk of delivering early, enabling obstetricians to implement early clinical interventions.
The record
- Vertical
- Women's Health
- Sub-segment
- Pregnancy risk diagnostics
- Product type
- Diagnostics
- Stage
- Public
- Headquarters
- Salt Lake City, USA
- Region
- North America
- Founded
- 2008
- Total funding
- $135M raised
Notable investors: Blue Ox Healthcare Partners, Domain Associates, Intermountain Healthcare.